The allotment status for the ₹9,275.22 crore Manipal Health Enterprises IPO is likely to be finalised today, August 3, 2026. Investors can check their IPO allotment status on the official websites of the NSE, BSE, and the IPO registrar, KFin Technologies Limited.
Following the completion of the allotment process, the shares are likely to be listed on the NSE and BSE on August 5, 2026.
Explore other Upcoming IPOs on BSE and NSE.
[July 31, 2026, 7:00 PM]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
8.25x |
|
Non-Institutional Investors (NIIs) |
1.02x |
|
Retail Individual Investors (RIIs) |
0.93x |
|
Employees |
2.19x |
|
Total |
4.92x |
The company intends to utilise the net proceeds from the fresh issue towards:
Explore other Upcoming IPOs on BSE and NSE.
Manipal Health Enterprises is one of India's prominent multispecialty healthcare providers, with a network of 49 hospitals and 13,037 licensed beds spread across 14 states and union territories as of March 31, 2026. The company is the largest private hospital chain in the country by bed capacity and ranks second in terms of the number of hospitals. In FY26, it catered to around 7.63 million patients and was supported by a network of 11,064 doctors.
The company focuses on delivering tertiary and quaternary healthcare services across specialties such as cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics, and renal sciences (CONGO-R). These segments accounted for 64.3% of its gross inpatient revenue during FY26. Manipal Health has expanded its footprint through acquisitions including AMRI Hospitals, Medica Synergie, and the Sahyadri Group. It also aims to increase its capacity by adding nearly 2,426 licensed beds by 2030.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
10,335.75 |
8,242.25 |
6,171.63 |
|
EBITDA |
2,795.94 |
2,247.07 |
1,776.60 |
|
Profit After Tax |
916.52 |
1,081.67 |
533.20 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.